you have more shares than me, I sold 500 on the way up so only have 500 left !!
did not see the AF bomb on PTCT, sold 40% of my position an hour ago. I will look for AF's heartwarming article.
I know I know - bulls make money, bears make money, pigs get slaughtered ... but isn't this a crown jewel ?
with everything going for it, and with JNJ patent problems with Remicade ?
I hear you, and ENDP SP will be higher than $85 if they end up bidding. I heard ENDP was selling a unit to Boston Scientific today, not sure if this is true.
Rare disease drugmaker PTC Therapeutics is exploring a potential sale amid takeover interest from several pharmaceutical companies, including Shire Plc and BioMarin Pharmaceutical Inc , according to people familiar with the matter. The company, which treats a muscle-wasting disorder known as Duchenne, is working with financial advisers as it weighs strategic alternatives, said the sources, who asked not to be named because the matter is private. Prosena Holding NV, which also makes a treatment for Duchenne, was acquired last November by BioMarin for $840 million. PTC Therapeutics' drug Translarna has received orphan drug status in the European Union and the United States and is in process of seeking U.S. Food and Drug Administration approval. Shire Plc could be interested in acquiring PTC Therapeutics to add to its portfolio of rare disease drugs, the sources added. Shire has made several acquisitions to bolster its focus on rare diseases, including a $5.2 billion purchase of NPS Pharmaceuticals in January and a $4.2 billion deal for ViroPharma last year. It also took a look at acquiring Salix Pharmaceuticals Ltd in recent weeks but ended up passing on the deal, according to sources